Clinical Trials
4 trialsNCT00804856 2023-10-03
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
Boehringer Ingelheim
Phase 2 Completed
NCT01721876 2023-02-08
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
Boehringer Ingelheim
Phase 3 Completed
NCT01662505 2018-07-30
Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)
Boehringer Ingelheim
Phase 1 Completed
NCT02722135 2017-01-27
A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed
Boehringer Ingelheim
Phase 1 Withdrawn